Oncolytics Biotech (NASDAQ:ONCY) Rating Lowered to “Moderate Buy” at Leede Financial

Oncolytics Biotech (NASDAQ:ONCY) was downgraded by stock analysts at Leede Financial from a “strong-buy” rating to a “moderate buy” rating in a research note issued on Wednesday,Zacks.com reports.

Separately, HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Oncolytics Biotech in a report on Thursday.

Oncolytics Biotech Stock Performance

Oncolytics Biotech stock traded down $0.03 during trading hours on Wednesday, reaching $0.98. 245,358 shares of the stock were exchanged, compared to its average volume of 328,224. The stock has a market cap of $75.53 million, a P/E ratio of -3.63 and a beta of 1.69. The firm’s 50 day moving average is $1.09 and its 200 day moving average is $1.06. Oncolytics Biotech has a 52-week low of $0.84 and a 52-week high of $1.75.

Institutional Trading of Oncolytics Biotech

An institutional investor recently bought a new position in Oncolytics Biotech stock. Virtu Financial LLC bought a new position in Oncolytics Biotech Inc. (NASDAQ:ONCY) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned about 0.07% of Oncolytics Biotech as of its most recent filing with the Securities and Exchange Commission (SEC). 6.82% of the stock is currently owned by institutional investors.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.